4.7 Article

Integrated Chinese and western medicine interventions for atopic dermatitis: a systematic review and meta-analysis

期刊

CHINESE MEDICINE
卷 16, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13020-021-00506-2

关键词

Atopic dermatitis; Integrated Chinese-Western medicine; Chinese medicine; Systematic review; Meta-analysis

资金

  1. Innovative Technology Commission of the Government of Hong Kong Special Administrative Region
  2. Dr. Barbara Kwok Integrative Medicine Research Fund

向作者/读者索取更多资源

This study systematically reviewed the clinical effectiveness and safety of integrated Chinese-Western medicine (ICWM) for atopic dermatitis (AD). The results showed that ICWM was superior to Western medicine alone in improving clinical severity of AD, health-related quality of life, long term control of AD, patients/investigator global score, and serum IgE level, with comparable adverse events. However, more evidence is needed for conclusive decision-making.
Background Atopic dermatitis (AD) is a chronic relapsing skin disease characterized by recurring episodes of itchiness with skin erythema and surface damages. Chinese medicine (CM) is widely used for the management of AD in China not only by its own, but also used in combination with conventional therapy (integrated Chinese-Western medicine, ICWM). Although many clinical trials on the effectiveness of ICWM on AD have been conducted, however, up to date, no sound evidence has been established on the clinical effectiveness and safety of ICWM for AD. Objectives To systematically review the currently available clinical evidence on the clinical effectiveness and safety of ICWM for AD. Methods Randomised and quasi-randomised controlled trials, which investigated ICWM interventions with at least one control group using the same conventional interventions, no treatment or placebo treatment, were included. Four English (CENTRAL, MEDLINE, EMBASE, AMED) and three Chinese (CNKI, CBM, WanFang Med) databases were searched. Risk of bias was assessed according to the Cochrane's tool. Meta-analysis was performed to pool the data. Results From 1473 entries, 55 studies were included, involving 5953 participants aged between 35 days and 67 years old. Duration of treatment ranged from 1 to 24 weeks. Only 2 studies were judged to have low risk of bias, 3 studies had unclear risk of bias, and the other 50 studies were with high risk of bias. ICWM was found to be superior over WM alone in improving clinical severity of AD (measured by EASI, SCORAD), health-related quality of life (measured by CDLQI, DLQI), long term control of AD (recurrence rate), patients/investigator global score (clinical effectiveness rate), and serum IgE level. Adverse events associated with ICWM were found to be comparable with WM alone. Conclusion ICWM seems to produce superior treatment response than WM alone in managing AD without increased risk of adverse events. However, the current available evidence remains too weak to make a conclusive decision.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据